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Background

1
Latham

• Non-Alcoholic Fatty Liver Disease (NAFLD) affects
more than 90% of patients with morbid obesity
(MO).
• NAFLD includes a spectrum of disease that begins
with simple steatosis (fatty change), then
steatohepatitis (NASH) in 10-15% and eventually
cirrhosis in 3-8%.
• Liver biopsy is the gold standard for diagnosis of
NASH and stages of fibrosis and cirrhosis; however,
several non-invasive blood tests have
demonstrated an ability to predict the presence or
absence of significant liver fibrosis in hepatitis.

Objectives
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• To determine the ability of non-invasive blood tests
(NAFLD, BARD, Fib-4, APRI) to predict liver biopsy
findings of significant fibrosis (SF) vs no significant
fibrosis (NSF) specifically in patients with MO.

Blood
Test

Parameters

NAFLD

Age, BMI, AST,
ALT, Platelet,
Albumin, DM

41.9% (13/31) 86.29% (107/124 )

BARD

BMI,AST, ALT,
DM

90.3% (28/31)

FIB-4

Age, AST, ALT,
Platelet

APRI

AST
Platelet

Sensitivity

3.23% (1/31)

Dibetes

16% (5/31)

Specificity

29.8% (37/124 )

100% (124/124)

99% (123/124)

No Diabetes

100%
80%
60%
40%

Design
v Liver biopsies from patients with MO undergoing
gastric bypass surgery were studied retrospectively.
Inclusion criteria :
2
2
• BMI ≥ 40 kg/m or > 35 kg/m with Diabetes or
hypertension
• Availability of data concerning sex, age, BMI,
Diabetes, platelet count, AST, ALT and albumin
within 6 months preceding surgery
Exclusion criteria :
• Any other potential cause of liver pathology
v Test cut-off scores for SF were set using available
on-line calculators.
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Conclusion
• No single non-invasive test showed sufficient
sensitivity and specificity to recommend it.
• Sequential combinations of these non-invasive test
results might improve their predictive value.
• Diabetes was associated with SF in patients with
MO and is likely to be a risk factor for progressive
liver fibrosis.
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